105 related articles for article (PubMed ID: 38735685)
1. Interleukine-10 in ovarian cancer.
Levin G; Gotlieb WH
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38735685
[TBL] [Abstract][Full Text] [Related]
2. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
3. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M; Yeku OO; Rafiq S; Purdon T; Dong X; Zhu L; Zhang T; Wang H; Yu Z; Mai J; Shen H; Nixon B; Li M; Brentjens RJ; Ma X
Nat Commun; 2020 Dec; 11(1):6298. PubMed ID: 33293516
[TBL] [Abstract][Full Text] [Related]
4. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
[TBL] [Abstract][Full Text] [Related]
5. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.
Batchu RB; Gruzdyn OV; Kolli BK; Dachepalli R; Umar PS; Rai SK; Singh N; Tavva PS; Weaver DW; Gruber SA
Adv Exp Med Biol; 2021; 1290():51-65. PubMed ID: 33559854
[TBL] [Abstract][Full Text] [Related]
6. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
[TBL] [Abstract][Full Text] [Related]
7. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.
Liu K; Huang A; Nie J; Tan J; Xing S; Qu Y; Jiang K
Front Immunol; 2021; 12():683332. PubMed ID: 34093586
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin-34: a key molecule in the tumor microenvironment].
Kajihara N; Seino KI
Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220
[TBL] [Abstract][Full Text] [Related]
9. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.
Aquino-Acevedo AN; Knochenhauer H; Castillo-Ocampo Y; Ortiz-León M; Rivera-López YA; Morales-López C; Cruz-Robles ME; Hernández-Cordero ER; Russell S; Whitaker R; Bonilla-Claudio M; Chen DT; Dutil J; Gaillard SL; Yi JS; Previs RA; Armaiz-Pena GN
Brain Behav Immun Health; 2022 Dec; 26():100558. PubMed ID: 36439058
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.
Pavicic PG; Rayman PA; Swaidani S; Rupani A; Makarov V; Tannenbaum CS; Edwards RP; Vlad AM; Diaz-Montero CM; Mahdi H
Oncoimmunology; 2023; 12(1):2198185. PubMed ID: 37066116
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
Brencicova E; Jagger AL; Evans HG; Georgouli M; Laios A; Attard Montalto S; Mehra G; Spencer J; Ahmed AA; Raju-Kankipati S; Taams LS; Diebold SS
PLoS One; 2017; 12(4):e0175712. PubMed ID: 28410380
[TBL] [Abstract][Full Text] [Related]
13. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
García-Martínez E; Redondo A; Piulats JM; Rodríguez A; Casado A
Angiogenesis; 2020 Nov; 23(4):543-557. PubMed ID: 32691290
[TBL] [Abstract][Full Text] [Related]
14. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
[TBL] [Abstract][Full Text] [Related]
15. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients.
Szulc-Kielbik I; Kielbik M; Nowak M; Klink M
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188639. PubMed ID: 34695534
[TBL] [Abstract][Full Text] [Related]
16. Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications.
Smida T; Bruno TC; Stabile LP
Front Oncol; 2020; 10():137. PubMed ID: 32133288
[TBL] [Abstract][Full Text] [Related]
17. Ascites IL-10 Promotes Ovarian Cancer Cell Migration.
Lane D; Matte I; Garde-Granger P; Bessette P; Piché A
Cancer Microenviron; 2018 Dec; 11(2-3):115-124. PubMed ID: 30039195
[TBL] [Abstract][Full Text] [Related]
18. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract][Full Text] [Related]
20. Immune Features of Tumor Microenvironment: A Genetic Spotlight.
Asadi M; Zarredar H; Zafari V; Soleimani Z; Saeedi H; Caner A; Shanehbandi D
Cell Biochem Biophys; 2024 Mar; 82(1):107-118. PubMed ID: 37870699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
